Cytokinetics (CYTK) Equity Average: 2009-2025
Historic Equity Average for Cytokinetics (CYTK) over the last 15 years, with Sep 2025 value amounting to -$444.9 million.
- Cytokinetics' Equity Average fell 1040.25% to -$444.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$444.9 million, marking a year-over-year decrease of 1040.25%. This contributed to the annual value of -$260.8 million for FY2024, which is 5.56% down from last year.
- Latest data reveals that Cytokinetics reported Equity Average of -$444.9 million as of Q3 2025, which was down 40.10% from -$317.6 million recorded in Q2 2025.
- In the past 5 years, Cytokinetics' Equity Average ranged from a high of $246.4 million in Q4 2021 and a low of -$444.9 million during Q3 2025.
- For the 3-year period, Cytokinetics' Equity Average averaged around -$252.2 million, with its median value being -$281.1 million (2023).
- As far as peak fluctuations go, Cytokinetics' Equity Average spiked by 419.92% in 2021, and later plummeted by 1,040.25% in 2025.
- Cytokinetics' Equity Average (Quarterly) stood at $246.4 million in 2021, then slumped by 125.13% to -$61.9 million in 2022, then tumbled by 566.08% to -$412.6 million in 2023, then spiked by 81.91% to -$74.6 million in 2024, then tumbled by 1,040.25% to -$444.9 million in 2025.
- Its last three reported values are -$444.9 million in Q3 2025, -$317.6 million for Q2 2025, and -$200.9 million during Q1 2025.